Treatment of hepatorenal syndrome

Pharmacotherapy

Volumn 29, Issue 10, 2009, Pages 1196-1211

  Kiser, Tyree H ^a   MacLaren, Robert ^a   Fish, Douglas N ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Ascites; Cirrhosis; Hepatorenal syndrome; HRS; Portal hypertension; Renal failure; Treatment

Indexed keywords

1 [3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL)ACRYLOYL]PIPERIDINE 2 ACETIC ACID; ALBUMIN; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DOPAMINE; FENOLDOPAM; FUROSEMIDE; MIDODRINE; N(G) METHYLARGININE; NESIRITIDE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; TERLIPRESSIN; TEZOSENTAN; THEOPHYLLINE; URODILATIN; VASOPRESSIN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALBUMIN DIALYSIS; ARTICLE; BRONCHOSPASM; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GRAFT SURVIVAL; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER SUPPORT; LIVER TRANSPLANTATION; MONOTHERAPY; PERIPHERAL ISCHEMIA; RENAL REPLACEMENT THERAPY; SHUNTING; TACHYCARDIA; THORAX PAIN;

HEPATORENAL SYNDROME; HUMANS; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RENAL REPLACEMENT THERAPY;

EID: 70349672706     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.10.1196     Document Type: Article

References (92)

1. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236 (Pubitemid 23234041)
2. Arroyo V, Gines P, Gerbes AL, et al, for the International Ascites Club. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-176 (Pubitemid 26012105)
3. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003;362:1819-1827
4. Brooks DP, Share L, Crofton JT. Central adrenergic control of vasopressin release. Neuroendocrinology 1986;42:416-420 (Pubitemid 16159922)
5. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 1988;319:1065-1072 (Pubitemid 18247994)
6. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(suppl 1):S69-89. (Pubitemid 36286564)
7. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-447 (Pubitemid 41061097)
8. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-1218 (Pubitemid 37314829)
9. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-1318 (Pubitemid 47300435)
10. Arroyo V, Terra C, Gines P. New treatments of hepatorenal syndrome. Semin Liver Dis 2006;26:254-264
11. Cardenas A, Arroyo V. Hepatorenal syndrome. Ann Hepatol 2003;2:23-29
12. Moller S, Bendtsen F, Henriksen JH. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome. Scand J Gastroenterol 2005;40:491-500. (Pubitemid 40676241)
13. Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006;1:1066-1079
14. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 1991;51:428-430
15. Jeyarajah DR, Gonwa TA, McBride M, et al. Hepatorenal syndrome: combined liver-kidney transplants versus isolated liver transplant. Transplantation 1997;64:1760-1765 (Pubitemid 28041715)
16. Gonwa TA, Poplawski S, Paulsen W, et al. Hepatorenal syndrome and orthotopic liver transplantation. Transplant Proc 1989;21(1 pt 2):2419-2420 (Pubitemid 19131279)
17. Gonwa TA, Poplawski S, Paulsen W, et al. Pathogenesis and outcome of hepatorenal syndrome in patients undergoing orthotopic liver transplant. Transplantation 1989;47:395-397 (Pubitemid 19069732)
18. Ruiz R, Kunitake H, Wilkinson AH, et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006;141:735-742 (Pubitemid 44268509)
19. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995;59:361-365
20. Lopez Lago AM, Fernandez Villanueva J, Garcia Acuna JM, Paz ES, Vizoso EF, Perez EV. Evolution of hepatorenal syndrome after orthotopic liver transplantation: comparative analysis with patients who developed acute renal failure in the early postoperative period of liver transplantation. Transplant Proc 2007;39:2318-2319 (Pubitemid 47418217)
21. Davis CL. Impact of pretransplant renal failure: when is listing for kidney-liver indicated? Liver Transpl 2005;11(11 suppl 2):S35-44.
22. Rimola A, Gavaler JS, Schade RR, el-Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology 1987;93:148-156 (Pubitemid 17084107)
23. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;35:1179-1185 (Pubitemid 34454015)
24. Campbell MS, Kotlyar DS, Brensinger CM, et al. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 2005;11:1048-1055
25. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004;40:140-146 (Pubitemid 38064723)
26. Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342:1701-1707 (Pubitemid 30354517)
27. Gerbes AL, Gulberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998;28:683-688 (Pubitemid 28405416)
28. Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416-422 (Pubitemid 28363668)
29. Brensing KA, Textor J, Perz J, et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in nontransplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-295 (Pubitemid 30489776)
30. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64. (Pubitemid 38868923)
31. Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997;349:697-698 (Pubitemid 27107750)
32. Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Buttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 1995;17:135-146
33. Witzke O, Baumann M, Patschan D, et al. Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol 2004;19:1369-1373
34. Capling RK, Bastani B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail 2004;26:563-568 (Pubitemid 39363289)
35. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-286 (Pubitemid 30317221)
36. Rifai K, Ernst T, Kretschmer U, et al. The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif 2005;23:298-302. (Pubitemid 41327801)
37. Rahman E, Al Suwaida AK, Askar A. Single-pass albumin dialysis in hepatorenal syndrome. Saudi J Kidney Dis Transpl 2008;19:479-484
38. Rosa Diez G, Greloni G, Gadano A, et al. Combined extended haemodialysis with single-pass albumin dialysis (SPAED). Nephrol Dial Transplant 2007;22:2731-2732 (Pubitemid 47365551)
39. Phua J, Lee KH. Liver support devices. Curr Opin Crit Care 2008;14:208-215
40. Stadlbauer V, Davies NA, Sen S, Jalan R. Artificial liver support systems in the management of complications of cirrhosis. Semin Liver Dis 2008;28:96-109. (Pubitemid 351326536)
41. McIntyre CW, Fluck RJ, Freeman JG, Lambie SH. Characterization of treatment dose delivered by albumin dialysis in the treatment of acute renal failure associated with severe hepatic dysfunction. Clin Nephrol 2002;58:376-383
42. Krisper P, Haditsch B, Stauber R, et al. In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. J Hepatol 2005;43:451-457
43. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003;9:290-297
44. Rifai K, Ernst T, Kretschmer U, et al. Prometheus: a new extracorporeal system for the treatment of liver failure. J Hepatol 2003;39:984-990 (Pubitemid 37523770)
45. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409 (Pubitemid 29362513)
46. Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-1359 (Pubitemid 351626950)
47. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36(4 pt 1):941-948
48. Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999;30:639-645 (Pubitemid 29151905)
49. Romanelli RG, La Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006;12:1403-1407
50. Peron JM, Bureau C, Gonzalez L, et al. Treatment of hepatorenal syndrome as defined by the International Ascites Club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol 2005;100:2702-2707 (Pubitemid 43919638)
51. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005;20:1813-1820 (Pubitemid 41222593)
52. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-930 (Pubitemid 34267275)
53. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-156 (Pubitemid 36349860)
54. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-1368 (Pubitemid 351615358)
55. Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008;53:830-835 (Pubitemid 351317073)
56. Testro AG, Wongseelashote S, Angus PW, Gow PJ. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol 2008;23:1535-1540
57. von Kalckreuth V, Glowa F, Geibler M, Lohse AW, Denzer UW. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study. Z Gastroenterol 2009;47:21-26
58. Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153-158 (Pubitemid 34163994)
59. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41. (Pubitemid 28041531)
60. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999;30:870-875 (Pubitemid 29458273)
61. Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology 2006;105:599-612; quiz 639-640 (Pubitemid 44310444)
62. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 1994;203:72-79 (Pubitemid 24281062)
63. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2006;(4):CD005162.
64. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006;24:935-944 (Pubitemid 44326374)
65. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-380 (Pubitemid 34810356)
66. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007;47:499-505. (Pubitemid 47331744)
67. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103:1689-1697
68. Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998;28:937-943 (Pubitemid 28450253)
69. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-1697 (Pubitemid 29247040)
70. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52:742-748 (Pubitemid 46303050)
71. Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome [published online ahead of print February 20, 2009]. J Clin Gastroenterol. Available from http://dx.doi.org/10.1097/MCG. 0b013e318188947c.
72. Vorobioff JD, Ferretti SE, Zangroniz P, et al. Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial. Am J Gastroenterol 2007;102:2206-2213 (Pubitemid 47493835)
73. Moller S, Brinch K, Henriksen JH, Becker U. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1997;26:1026-1033 (Pubitemid 27242592)
74. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38:238-243 (Pubitemid 36775816)
75. Kalambokis G, Economou M, Fotopoulos A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005;100:879-885
76. Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 2008;117:200-205
77. Salo J, Gines A, Quer JC, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996;25:916-923 (Pubitemid 27008125)
78. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001;29:1526-1531 (Pubitemid 32762331)
79. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J, for the Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet 2000;356:2139-2143 (Pubitemid 32047951)
80. Brienza N, Malcangi V, Dalfino L, et al. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Crit Care Med 2006;34:707-714 (Pubitemid 43308260)
81. Hadengue A, Moreau R, Bacq Y, Gaudin C, Braillon A, Lebrec D. Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study. Hepatology 1991;13:111-116
82. Wong F, Moore K, Dingemanse J, Jalan R. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology 2008;47:160-168 (Pubitemid 351171053)
83. Carstens J, Greisen J, Jensen KT, Vilstrup H, Pedersen EB. Renal effects of a urodilatin infusion in patients with liver cirrhosis, with and without ascites. J Am Soc Nephrol 1998;9:1489-1498 (Pubitemid 28354560)
84. Carstens J, Gronbaek H, Larsen HK, Pedersen EB, Vilstrup H. Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention [online exclusive article]. BMC Gastroenterol 2007;7:1. Available from http://www.biomedcentral.com/1471-230X/7/1.
85. Meyer M, Pfarr E, Schirmer G, et al. Therapeutic use of the natriuretic peptide ularitide in acute renal failure. Ren Fail 1999;21:85-100. (Pubitemid 29085227)
86. Forrest EH, Bouchier IA, Hayes PC. Acute effect of low-dose theophylline on the circulatory disturbances of cirrhosis. Gut 1997;40:139-144
87. Stanley AJ, Forrest EH, Dabos K, Bouchier IA, Hayes PC. Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites. Gastroenterology 1998;115:406-411 (Pubitemid 28363433)
88. Gentilini P, Romanelli RG, La Villa G, et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 1993;104:588-594 (Pubitemid 23033435)
89. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999;29:334-339 (Pubitemid 29088434)
90. 2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 1993;17:220-226
91. La Villa G, Barletta G, Pantaleo P, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001;34:19-27. (Pubitemid 32591478)
92. Thiesson HC, Skott O, Jespersen B, Schaffalitzky de Muckadell OB. Nitric oxide synthase inhibition does not improve renal function in cirrhotic patients with ascites. Am J Gastroenterol 2003;98:180-186 (Pubitemid 36135188)